Shimadzu and Phenomenome Discoveries Announce Exclusive Collaboration
News Jul 02, 2007
Shimadzu Corporation and Phenomenome Discoveries Inc (PDI) have agreed to integrate high mass accuracy mass spectrometry data generated on Shimadzu Corporation's LCMS-IT-TOF systems with the Phenomenome Profiler™ informatics platform.
This announcement further combines the Shimadzu Corporation's mass spectrometry product line with PDI's software tools to visualize and interpret data for biomarker discovery and global profiling studies including comparative proteomic studies.
Kozo Shimazu, Corporate Officer, Deputy General manager For Mass Spectrometry, at Shimadzu Corporation, stated, “Our collaboration with PDI has been enhanced to take into account the growing need of researchers working in biomarker discovery and comparative proteomics studies to use high mass accuracy MSn data.”
Mr. Shimazu added, “We believe that this collaboration further strengthens the relationship between Shimadzu Corporation and PDI and helps deliver a unique and integrated solution to help find components of biologically significance.”
John Hyshka, COO of Phenomenome Discoveries, said “Our agreement with Shimadzu Corporation allows investigators working in global profiling to find and identify key markers for disease using innovative mass spectrometry technology. This agreement reflects our growing commitment to develop new tools for advancing research into working with large data sets to identify key markers for disease.”
Prostate- and Colon Cancer Targeted With Tapeworm DrugNews
Recently researchers found that a substance in medicine against parasites like Giardia and Tapeworms, acts like tailored medicine against prostate- and colon cancer.READ MORE
Engineering the Gut Microbiome with 'Good' Bacteria May Help Treat Crohn's DiseaseNews
Researchers have singled out a bacterial enzyme behind an imbalance in the gut microbiome linked to Crohn's disease. Replacement of the offending bacteria with "good" bacteria may offer an effective treatment approach.READ MORE
New Player in Alzheimer's Disease Pathogenesis IdentifiedNews
Using proteomics, microscopic analysis, and functional assays, scientists have shown that a protein called membralin is critical for keeping Alzheimer’s disease pathology in check.READ MORE